Change in basal ganglia volume over 2 years in patients with schizophrenia: typical versus atypical neuroleptics.

OBJECTIVE For many years, it has been assumed that medications affect brain chemistry and physiology but not structure. Recent reports suggest that neuroleptic medication changes basal ganglia volume. To explore this possibility, the authors assessed for basal ganglia volume change in individuals who had their basal ganglia structures delineated and measured on magnetic resonance scans at the beginning and end of a 2-year period and who received neuroleptic medication during this time. METHOD The basal ganglia volumes of 23 male patients with schizophrenia spectrum disorders were measured from manual traces delineating the caudate and lenticular nucleus on magnetic resonance images at admission and 2 years later. Patients' neuroleptic exposure was calculated over the 2 years by using a dose-year formula. RESULTS During the 2-year period, mean basal ganglia volume of patients receiving predominantly typical neuroleptics increased, while the opposite was observed for patients receiving mostly atypical neuroleptics. Correlation analysis for the entire group showed a positive relationship between the 2-year exposure to typical neuroleptic medication and change in basal ganglia volume and the reverse for exposure to atypical neuroleptics. CONCLUSIONS In this group, basal ganglia volume increased following exposure to typical neuroleptics and decreased following exposure to atypical neuroleptics.

[1]  M. Keshavan,et al.  Changes in caudate volume with neuroleptic treatment , 1994, The Lancet.

[2]  Cynthia G. Wible,et al.  Caudate, putamen, and globus pallidus volume in schizophrenia: A quantitative MRI study , 1995, Psychiatry Research: Neuroimaging.

[3]  S. Heckers,et al.  Cortex, white matter, and basal ganglia in schizophrenia: A volumetric postmortem study , 1991, Biological Psychiatry.

[4]  N C Andreasen,et al.  The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. , 1992, Archives of general psychiatry.

[5]  James C. Ehrhardt,et al.  Subcortical and temporal structures in affective disorder and schizophrenia: A magnetic resonance imaging study , 1992, Biological Psychiatry.

[6]  Manzar Ashtari,et al.  Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine , 1995, The Lancet.

[7]  P Riederer,et al.  Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. , 1987, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[8]  E. Bird,et al.  Organization of dopamine D1 and D2 receptors in human striatum: Receptor autoradiographic studies in Huntington's disease and schizophrenia , 1988, Synapse.

[9]  N. C. Andreasen,et al.  The concept of dose years: A reliable method for calculating lifetime psychotropic drug exposure , 1995, Schizophrenia Research.

[10]  N. Andreasen,et al.  Effect of Antipsychotics on Regional Cerebral Blood Flow Measured with Positron Emission Tomography , 1997, Neuropsychopharmacology.

[11]  S. Olson,et al.  Increased caudate volume in schizophrenia: A controlled MRI study , 1993, Schizophrenia Research.

[12]  John M. Davis.  Dose equivalence of the anti-psychotic drugs , 1974 .

[13]  R. Buchanan,et al.  Basal ganglia pathology in schizophrenia and tardive dyskinesia: an MRI quantitative study. , 1994, The American journal of psychiatry.

[14]  N C Andreasen,et al.  Image processing for the study of brain structure and function: problems and programs. , 1992, The Journal of neuropsychiatry and clinical neurosciences.

[15]  J. Hyttel,et al.  Differentiation of classical and novel antipsychotics using animal models , 1997 .

[16]  E. Pehek,et al.  Differential Effects of Locally Administered Clozapine and Haloperidol on Dopamine Efflux in the Rat Prefrontal Cortex and Caudate‐Putamen , 1994, Journal of neurochemistry.

[17]  A. Graybiel.  The basal ganglia and cognitive pattern generators. , 1997, Schizophrenia bulletin.

[18]  K. Krishnan,et al.  Neuroleptic treatment and caudate plasticity , 1995, The Lancet.

[19]  N. Andreasen,et al.  The effect of antipsychotic medication on relative cerebral blood perfusion in schizophrenia: Assessment with technetium-99m hexamethyl-propyleneamine oxime single photon emission computed tomography , 1997, Biological Psychiatry.

[20]  M. Flaum,et al.  435 The effecf of cumulative neuroleptic exposure on caudate and putamen volumes , 1997, Schizophrenia Research.

[21]  J. Lieberman,et al.  Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. , 1994, The American journal of psychiatry.

[22]  Peter J Ell,et al.  Limbic selectivity of clozapine , 1997, The Lancet.

[23]  J N Giedd,et al.  Childhood-onset schizophrenia: brain MRI rescan after 2 years of clozapine maintenance treatment. , 1996, The American journal of psychiatry.

[24]  D L Braff,et al.  Magnetic resonance imaging abnormalities in lenticular nuclei and cerebral cortex in schizophrenia. , 1991, Archives of general psychiatry.

[25]  G. Sedvall,et al.  Recent developments in PET scan imaging of neuroreceptors in schizophrenia. , 1995, The Israel journal of psychiatry and related sciences.

[26]  G D Pearlson,et al.  Neuroimaging in schizophrenia research. , 1993, Schizophrenia bulletin.

[27]  R. Buchanan,et al.  Brain morphology and schizophrenia. A magnetic resonance imaging study of limbic, prefrontal cortex, and caudate structures. , 1992, Archives of general psychiatry.